MEDDDICAL has announced the launch of a real-world evidence (RWE) advisory service for pharmaceutical and biotech teams ...

While UK biotech financing recovery is present in the private markets, BIA CEO Chris Molloy notes that UK public sector backing is essential for sustained growth.

The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2026" has been added to ResearchAndMarkets.com's offering.The Co-promotion and Co-marketing Deals in Pharmaceuticals and ...

Biogen has found a successor to longtime legal chief Susan Alexander, tapping former Vertex Pharmaceuticals executive and ...

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to ...

Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply A growing number of ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.87% at $2.89. This change lagged the S&P 500's daily loss of 0.19%. At the same time, the Dow lost 0.59%, and the tech-heavy ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has dominated the cystic fibrosis (CF) drug market for more than a decade. This has ...

China aims to overtake the United States in biopharma by running the same playbook it has employed in other sectors: a ...

Collegium's CEO cited talent as one key reason the biotech is relocating from its longtime home in Stoughton to Boston’s ...

Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?